



SEQUENCE LISTING

<110> Fuji Yakuhin Kogyo Kabushiki Kaisha

<120> Monoclonal Antibody against Canine Trypsin

<130> FJ-94PCT

<140>

<141>

<150> JP 10-236609

<151> 1998-08-10

<150> JP 11-63990

<151> 1999-03-10

<160> 5

<170> PatentIn Ver. 2.0

<210> 1

<211> 247

<212> PRT

<213> Dog Pancreas

<400> 1

Met Asn Pro Leu Leu Ile Leu Ala Phe Leu Gly Ala Ala Val Ala Thr

1

5

10

15

Pro Thr Asp Asp Asp Asp Lys Ile Val Gly Gly Tyr Thr Cys Glu Glu

20

25

30

Asn Ser Val Pro Tyr Gln Val Ser Leu Asn Ala Gly Tyr His Phe Cys

35

40

45

Gly Gly Ser Leu Ile Ser Asp Gln Trp Val Val Ser Ala Ala His Cys

50

55

60

Tyr Lys Ser Arg Ile Gln Val Arg Leu Gly Glu Tyr Asn Ile Asp Val

65

70

75

80

Leu Glu Gly Asn Glu Gln Phe Ile Asn Ser Ala Lys Val Ile Arg His

85

90

95

Pro Asn Tyr Asn Ser Trp Ile Leu Asp Asn Asp Ile Met Leu Ile Lys

100

105

110

Leu Ser Ser Pro Ala Val Leu Asn Ala Arg Val Ala Thr Ile Ser Leu

115

120

125

Pro Arg Ala Cys Ala Ala Pro Gly Thr Gln Cys Leu Ile Ser Gly Trp

130

135

140

Gly Asn Thr Leu Ser Ser Gly Thr Asn Tyr Pro Glu Leu Leu Gln Cys

145

150

155

160

Leu Asp Ala Pro Ile Leu Thr Gln Ala Gln Cys Glu Ala Ser Tyr Pro

165

170

175

Gly Gln Ile Thr Glu Asn Met Ile Cys Ala Gly Phe Leu Glu Gly Gly

180

185

190

Lys Asp Ser Cys Gln Gly Asp Ser Gly Gly Pro Val Val Cys Asn Gly

195

200

205

Glu Leu Gln Gly Ile Val Ser Trp Gly Tyr Gly Cys Ala Gln Lys Asn

210

215

220

Lys Pro Gly Val Tyr Thr Lys Val Cys Asn Phe Val Asp Trp Ile Gln

225

230

235

240

Ser Thr Ile Ala Ala Asn Ser

245

<210> 2

<211> 246

<212> PRT

<213> Dog Pancreas

<400> 2

Met Lys Thr Phe Ile Phe Leu Ala Leu Leu Gly Ala Thr Val Ala Phe

1

5

10

15

Pro Ile Asp Asp Asp Asp Lys Ile Val Gly Gly Tyr Thr Cys Ser Arg

20

25

30

Asn Ser Val Pro Tyr Gln Val Ser Leu Asn Ser Gly Tyr His Phe Cys

35

40

45

Gly Gly Ser Leu Ile Asn Ser Gln Trp Val Val Ser Ala Ala His Cys

50

55

60

Tyr Lys Ser Arg Ile Gln Val Arg Leu Gly Glu Tyr Asn Ile Ala Val

65

70

75

80

Ser Glu Gly Gly Glu Gln Phe Ile Asn Ala Ala Lys Ile Ile Arg His

85

90

95

Pro Arg Tyr Asn Ala Asn Thr Ile Asp Asn Asp Ile Met Leu Ile Lys

100

105

110

Leu Ser Ser Pro Ala Thr Leu Asn Ser Arg Val Ser Ala Ile Ala Leu

115

120

125

Pro Lys Ser Cys Pro Ala Ala Gly Thr Gln Cys Leu Ile Ser Gly Trp

130

135

140

Gly Asn Thr Gln Ser Ile Gly Gln Asn Tyr Pro Asp Val Leu Gln Cys

145

150

155

160

Leu Lys Ala Pro Ile Leu Ser Asp Ser Val Cys Arg Asn Ala Tyr Pro

165

170

175

Gly Gln Ile Ser Ser Asn Met Met Cys Leu Gly Tyr Met Glu Gly Gly

180

185

190

Lys Asp Ser Cys Gln Gly Asp Ser Gly Gly Pro Val Val Cys Asn Gly

195

200

205

Glu Leu Gln Gly Val Val Ser Trp Gly Ala Gly Cys Ala Gln Lys Gly

210

215

220

Lys Pro Gly Val Ser Pro Lys Val Cys Lys Tyr Val Ser Trp Ile Gln

225

230

235

240

Gln Thr Ile Ala Ala Asn

245

<210> 3

<211> 20

<212> PRT

<213> Artificial Sequence



<220>

<223> Description of Artificial Sequence: Designed

peptide to act as an immunogen

<400> 3

Cys Leu Ile Ser Gly Trp Gly Asn Thr Gln Ser Ile Gly Gln Asn Tyr

1

5

10

15

Pro Asp Val Leu

20

<210> 4

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Designed

peptide to act as an immunogen

<400> 4

Ile Val Gly Gly Tyr Thr Cys Ser Arg Asn Ser Val Pro Tyr Gln Val

1

5

10

15

Ser Leu Asn Ser

20

<210> 5

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Designed

peptide to act as an immunogen

<400> 5

Leu Gln Gly Val Val Ser Trp Gly Ala Gly Cys Ala Gln Lys Gly Lys

1

5

10

15

Pro Gly Val Ser

20